What is the use of Methylene blue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Methylene blue is primarily used to treat methemoglobinemia, a condition where blood cannot properly carry oxygen, at doses of 1-2 mg/kg administered intravenously, as recommended by the American Journal of Hematology in 2021 1. The treatment of methemoglobinemia with methylene blue involves administering the medication intravenously over 3 to 5 minutes, with a usual starting dose of 1–2 mg/kg (0.2 mL/kg of a 1% solution) 1. Key points to consider when using methylene blue for this purpose include:

  • The dose may be repeated at 1 mg/kg if methemoglobinemia does not significantly decrease within 30–60 minutes 1
  • Methylene blue should reduce MetHb levels significantly in less than an hour 1
  • Risk of worsening of methemoglobinemia increases with repeated doses, with toxic levels of MB reached at a total dose > 7 mg/kg 1
  • A rebound phenomenon of increased MetHb levels after completion of therapy is attributed to the reversal of the reduction reaction 1 In cases where methemoglobinemia is caused by a long-acting oxidant stress, such as after dapsone ingestion, repeat dosing every 6–8 hours for up to 2–3 days or a continuous IV infusion of 0.10–0.25 mg/kg/hr may be necessary 1.

From the FDA Drug Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1768-1 Methylene Blue Injection, USP 50 mg/10 mL (5 mg/mL) Intravenous use only Single-Dose vial Rx only NDC 70771-1768-5 Methylene Blue Injection, USP 50 mg/10 mL (5 mg/mL) Intravenous use only 5 X 10 mL Single-Dose Vial Rx only NDC 70771-1767-1 Methylene Blue Injection, USP 10 mg/2 mL (5 mg/mL) Intravenous use only Single-Dose vial Rx only NDC 70771-1767-5 Methylene Blue Injection, USP 10 mg/2 mL (5 mg/mL) Intravenous use only 5 X 2 mL Single-Dose Vial Rx only

The FDA drug label does not answer the question.

From the Research

Uses of Methylene Blue

  • Methylene blue is used to treat methemoglobinemia, a disorder characterized by the presence of >1% methemoglobin in the blood 2, 3, 4.
  • It acts by providing an artificial electron acceptor for NADPH methemoglobin reductase, which helps to reduce methemoglobin to hemoglobin 2.
  • The typical dose of methylene blue for treating methemoglobinemia is 1-2 mg/kg administered slow intravenously 2, 3, 4.
  • Methylene blue can also be used to treat refractory hypotension, as seen in a case report where a 22-month-old girl with septic shock was treated with intravenous methylene blue 5.
  • Additionally, methylene blue has been explored as a potential treatment for other conditions, but its primary use remains in the treatment of methemoglobinemia.

Important Considerations

  • Methylene blue should be used with caution in patients with known or suspected glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it can exacerbate the condition 2, 3, 4.
  • The effectiveness of methylene blue can be reduced in the presence of haemolysis, and high doses can even initiate methaemoglobin formation 4.
  • Alternative treatments, such as hyperbaric oxygenation monotherapy, may be considered when methylene blue is not available or effective 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Blue cures blue but be cautious.

Journal of pharmacy & bioallied sciences, 2011

Research

Methylene blue.

American journal of therapeutics, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.